摘要
慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是人类最重要的致死性和致残性疾病之一,但是除了吸入支气管舒张剂和糖皮质激素外,其他真正有效的治疗药物非常有限。本文探讨了Ⅰ级和Ⅱ级COPD患者应用长效支气管舒张剂治疗的必要性,以及抗氧化剂、维生素D、大环内酯类抗生素治疗COPD的机制、争议和进展;也展望了一些COPD新药开发的切入点,如阻断气道的炎症反应通路、肺泡上皮细胞修复等,并指出单独使用肺功能检查作为COPD诊断、评估和治疗的手段价值有限,可进一步识别COPD的表型来指导COPD的治疗。
Chronic Obstructive Pulmonary Disease（COPD） is one of most important lethal and disabling diseases in human beings, but its effective treatments are limited except by bronchodilators and glueocorticoids. This paper discusses the necessity of long acting hronchodilators therapies in Stage Ⅰ and Ⅱ in COPD, as well as some mechanisms, controversy and advances of non-conventional pharmacologic therapies such as antioxidants, Vitamin D and macrolide antibiotics in patients with COPD. The paper also forecasts some new pharmacologic targets in treatment of COPD, such as inflammatory pathway blockade and alveolar epithelial cell repair. The paper points out that because of limited value in measures of diagnosis, and assessment, it is necessary to treat COPD according to single lung function parameter, and phenotype of COPD, which is helpful in directing treatment of COPD.
出处
《临床误诊误治》
2012年第8期8-12,共5页
Clinical Misdiagnosis & Mistherapy
基金
上海市慢性病综合防治项目(SHDC12007301)
关键词
肺疾病
慢性阻塞性
药物疗法
Pulmonary disease, chronic obstructive
Drug therapy
